For laboratory and research use only. Not for human consumption.
Skin & Hair

SYN-AKE

Also known as: Dipeptide diaminobutyroyl benzylamide diacetate, SYN-AKE, Syn-Ake, Tripeptide-3, beta-Ala-Pro-Dab-NH-benzyl

Research
Share:
Last reviewed

Key Facts: SYN-AKE

Category
Skin & Hair
FDA Status
Not FDA Approved
Clinical Status
Cosmetic ingredient in anti-wrinkle creams and serums. Not an FDA-approved drug: cosmetics and their ingredients (except color additives) do not need FDA approval before sale, and SYN-AKE has never been through drug trials. Efficacy data is small and manufacturer-funded.
Banned in Sport (WADA)
Not on the WADA Prohibited List (2026). It is a topical cosmetic ingredient, and skincare use is not a known anti-doping issue.
Administration
Topical (serums, creams)
Typical Dose
1-4% of the SYN-AKE solution in a finished product
Frequency
Once or twice daily
Duration
28 days in the manufacturer study; ongoing use to maintain any effect
Also Known As
Dipeptide diaminobutyroyl benzylamide diacetate, SYN-AKE, Syn-Ake, Tripeptide-3, beta-Ala-Pro-Dab-NH-benzyl

How does SYN-AKE work?

DSM describes SYN-AKE as a reversible blocker of the muscle-type nicotinic acetylcholine receptor, the receptor on muscle that acetylcholine opens to make it contract. Block it, the theory goes, and facial muscles relax a little. That is the real mechanism of Waglerin-1, a 22-amino-acid viper toxin that independent research shows selectively blocks the adult form of this receptor. SYN-AKE itself is a much smaller molecule (beta-alanine, proline and diaminobutyric acid with a benzylamide end, under 500 daltons), and the claim that it does the same thing comes from the manufacturer's own cell test, where innervated muscle cells contracted less. Even DSM's older material calls the binding 'probable'. As with Argireline, there is no independent proof that a cream gets enough of it to facial muscle to matter.

What does the research show?

DSM's brochure reports two pieces of data. In vitro, 0.5 mM of the peptide cut the contraction frequency of innervated muscle cells. In vivo, a 4% SYN-AKE cream was compared with placebo in 15 volunteers per group (aged 40-60), applied twice daily for 28 days, with reductions of roughly 15-21% in skin roughness and wrinkle measures and a headline of 'up to 52%' wrinkle reduction in the best responders. A US patent also describes a double-blind study in 59 women aged 40-55 reporting smaller pores and less shine after 28 days, but that is a patent filing, not a peer-reviewed paper. A 2020 review of cosmetic peptides states plainly that there are no scientific papers describing clinical studies of this peptide, so the efficacy story rests on company data. Bottom line: a well-tolerated cosmetic ingredient with a catchy story. The venom angle is marketing, and the 'up to 52%' number is a best case from a 15-person company study, not a typical result.

Trial Progress:Preclinical
Pre
I
II
III
IV
FDA

What doses have been studied?

Limited Research·Only manufacturer cell and small volunteer studies; no peer-reviewed clinical papers

Typical Dosingⓘ

Community experience

Common Dose

1-4% of the SYN-AKE solution in a finished product

Range

1-4% (manufacturer suggested range)

Frequency

Once or twice daily

These are cosmetic formulation levels, not personal doses. There is no injectable or oral use with human data, and the venom-mimic framing does not mean it acts like an injectable neurotoxin.

Research Dosingⓘ

Scientific studies

Typical cosmetic formulation levels from manufacturer data. Not a dosing recommendation.

Doses from Studies

Suggested concentration 1-4% SYN-AKE

Manufacturer data (DSM) - SYN-AKE brochure 2020 ↗

4% cream twice daily for 28 days vs placebo (15 per group, age 40-60)

Manufacturer data (DSM) - SYN-AKE brochure 2020 ↗

Duration

28 days in the manufacturer study; ongoing use to maintain any effect

Administration

Topical (serums, creams)

When and how is SYN-AKE taken?

Best Time to Take

Morning and/or evening, on clean skin

Once or twice daily, ongoing

Food Recommendation

With or without food

Why This Timing?

Timing has no known effect on a topical peptide; the manufacturer study used twice-daily application.

What are the side effects of SYN-AKE?

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Generally well tolerated in cosmetic use
  • ●Mild tingling, redness or irritation (uncommon)
  • ●Contact allergy possible, as with any skincare ingredient
  • ●Does not paralyze muscles the way botulinum toxin injections do

References

Research This Peptide Further

Frequently Asked Questions

What does SYN-AKE do?

SYN-AKE is DSM's trade name for dipeptide diaminobutyroyl benzylamide diacetate, the 'snake venom' peptide in a lot of anti-wrinkle creams. The marketing says it mimics Waglerin-1, a toxin from the temple viper. To be clear: there is no venom in it. It is a tiny synthetic molecule, and the evidence that it relaxes wrinkles comes almost entirely from the manufacturer.

How does SYN-AKE work?

DSM describes SYN-AKE as a reversible blocker of the muscle-type nicotinic acetylcholine receptor, the receptor on muscle that acetylcholine opens to make it contract. Block it, the theory goes, and facial muscles relax a little. That is the real mechanism of Waglerin-1, a 22-amino-acid viper toxin that independent research shows selectively blocks the adult form of this receptor. SYN-AKE itself is a much smaller molecule (beta-alanine, proline and diaminobutyric acid with a benzylamide end, under 500 daltons), and the claim that it does the same thing comes from the manufacturer's own cell test, where innervated muscle cells contracted less. Even DSM's older material calls the binding 'probable'. As with Argireline, there is no independent proof that a cream gets enough of it to facial muscle to matter.

Is SYN-AKE FDA approved?

No, SYN-AKE is not currently FDA approved. Current status: Cosmetic ingredient in anti-wrinkle creams and serums. Not an FDA-approved drug: cosmetics and their ingredients (except color additives) do not need FDA approval before sale, and SYN-AKE has never been through drug trials. Efficacy data is small and manufacturer-funded.

Is SYN-AKE banned in sport?

Not on the WADA Prohibited List (2026). It is a topical cosmetic ingredient, and skincare use is not a known anti-doping issue.

What are the side effects of SYN-AKE?

Reported side effects include: Generally well tolerated in cosmetic use, Mild tingling, redness or irritation (uncommon), Contact allergy possible, as with any skincare ingredient, Does not paralyze muscles the way botulinum toxin injections do. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of SYN-AKE?

Community-reported common dose: 1-4% of the SYN-AKE solution in a finished product (Once or twice daily). Range: 1-4% (manufacturer suggested range). Administration: Topical (serums, creams). Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with SYN-AKE or used in similar applications.

GHK-Cu

Clinical Trials

GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.

Skin & Hair

Snap-8

Research

SNAP-8 (Acetyl Octapeptide-3) is a synthetic eight-amino-acid topical cosmetic peptide, an extended cousin of Argireline that adds two residues to the same SNAP-25 mimic sequence. It is marketed as a needle-free way to soften expression lines, especially on the forehead and around the eyes. It is a cosmetic ingredient, not an approved drug, and the human evidence behind it is thin and mostly comes from the manufacturer.

Skin & Hair

Argireline

Research

Argireline is the trade name for acetyl hexapeptide-8 (sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, also called acetyl hexapeptide-3), a synthetic peptide sold in anti-aging creams as a topical, needle-free alternative to Botox. It is designed to relax the muscle contractions behind expression lines. It is a cosmetic ingredient, not an FDA-approved drug, and the human efficacy data are genuinely mixed rather than settled.

Skin & Hair

Matrixyl

Research

Matrixyl is the trade name (Sederma) for palmitoyl pentapeptide-4, also written Pal-KTTKS, a collagen-fragment peptide attached to a fatty acid so it can cross skin. Unlike Botox-mimic peptides, it does not touch muscle: it signals skin cells to rebuild collagen, so it is aimed at fine lines, firmness and skin texture rather than expression wrinkles. It is a cosmetic ingredient with one of the better-documented topical studies in the peptide space, though far short of drug-grade proof.

Skin & Hair

Matrixyl 3000

Research

Matrixyl 3000 is Sederma's follow-up to the original Matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. It is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence.

Skin & Hair

Copper Peptide AHK-Cu

Research

AHK-Cu is a synthetic copper-bound tripeptide, alanine-histidine-lysine complexed with a copper ion, engineered mainly for hair and scalp products. It is the lesser-known sibling of the naturally occurring GHK-Cu copper peptide, designed in the lab specifically to push hair follicles to keep growing. It is a cosmetic and research ingredient, not an approved hair-loss drug, and its evidence is essentially limited to one notable lab study.

Skin & Hair

Want updates on SYN-AKE research?

Get an email when we add new research here, when it is back in stock, or when the price drops.